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Abstract: “Childhood glaucoma” is a heterogeneous group of severe pediatric conditions often 
associated with significant visual loss and characterized by elevated intraocular pressure (IOP) 
and optic-disk cupping. Successful IOP control is crucial but challenging and most often achieved 
surgically, with medical therapy playing a supportive role. There are many classifications of 
childhood glaucoma, but they can simply be divided into primary, in which a developmental 
abnormality of the anterior chamber angle only exists, and secondary, in which aqueous outflow 
is reduced due to independent mechanisms that secondarily impair the function of the filtration 
angle. The worldwide prevalence of childhood blindness ranges from 0.03% in high-income 
countries to 0.12% in undeveloped countries. The majority of cases do not have an identified 
genetic mutation and, where the mutation is known, the genes often account for only a small 
proportion of cases. Several pathogenetic mechanisms are known to contribute to the  development 
of childhood glaucoma. Whatever the cause, it results in a reduced aqueous outflow at the level of 
the trabecular meshwork. Age of onset and magnitude of the elevated IOP largely determine the 
clinical manifestation the high variability of clinical manifestations. Glaucoma from any cause in 
a neonate and infant is characterized by the classic triad of epiphora, photophobia, and blephar-
ospasm, and could be associated with eye enlargement (buphthalmos) and Haab striae. The eye 
examination, usually performed under general anesthesia, includes: tonometry, anterior-segment 
examination, gonioscopy, corneal diameter and axial length measurement, dilated fundoscopy 
with optic-nerve-head evaluation. Medical therapy, considering the high frequency of side effects, 
is generally used as temporizing IOP-lowering treatment before surgery or as adjuvant treatment 
postoperatively in case of partially successful procedures for refractory glaucomas. Surgery is 
the nodal point of the management of refractory childhood glaucoma, so it is crucial to opt for a 
forward-looking strategy to reach the target IOP and minimize the visual loss.
Keywords: childhood glaucoma, congenital glaucoma, glaucoma surgical therapy, childhood 
visual loss
Introduction
“Childhood glaucoma” is a rare and severe pediatric condition often associated with 
significant visual loss. It consists of a heterogeneous group of diseases characterized 
by elevated intraocular pressure (IOP) and optic-disk cupping. Successful control 
of IOP is crucial but challenging and most often achieved surgically, with medical 
therapy playing a supportive role.
Classification
There are many classifications of childhood glaucoma, but they can simply be classi-
fied as primary, in which a developmental abnormality of the anterior chamber (AC) 
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angle only exists, and secondary, in which aqueous outflow 
is reduced due to independent mechanisms that secondarily 
impair the function of the filtration angle1 (Table 1). Primary 
glaucoma in children is generally divided based on age of 
onset into primary congenital glaucoma (PCG), from birth to 
early childhood, and juvenile primary open-angle glaucoma 
(JOAG), from 4 years to early adulthood. Secondary glau-
coma includes a variety of conditions resulting from damage 
to the aqueous outflow system due to congenital or acquired 
ocular diseases or systemic disorders.
Table 1 Classification of childhood glaucoma
Primary childhood glaucoma
Primary congenital glaucoma
 Neonatal or newborn onset (0–1 month)
 infantile onset (.1–24 months)
 Late onset or late-recognized (.24 months)
Juvenile open-angle glaucoma
Secondary childhood glaucoma
Glaucoma associated with a non-acquired ocular anomaly
 Axenfeld–Rieger anomaly (syndrome if systemic associations)
 Peters anomaly (syndrome if systemic associations)
 ectropion uveae
 Congenital iris hypoplasia
 Aniridia
 Persistent fetal vasculature (if glaucoma present before cataract surgery)
 Oculodermal melanocytosis (nevus of Ota)
 Posterior polymorphous dystrophy
 Microphthalmos
 Microcornea
 ectopia lentis
Glaucoma associated with a non-acquired systemic disease or syndrome
 Chromosomal disorders such as trisomy 21 (Down syndrome)
 Connective tissue disorders
 Marfan syndrome
 weill–Marchesani syndrome
 Stickler syndrome
 Metabolic disorders
 Homocystinuria
 Lowe syndrome
 Mucopolysaccharidoses
 Phacomatoses
 Neurofibromatosis (NF-1, NF-2)
 Sturge–weber syndrome
 Klippel–Trénaunay–weber syndrome
 Rubinstein–Taybi syndrome
 Congenital rubella
Glaucoma associated with an acquired condition
 Uveitis
 Trauma (hyphema, angle recession, ectopia lentis)
 Steroid induced
 Tumors (benign/malignant, ocular/orbital)
 Retinopathy of prematurity
 Glaucoma following cataract surgery
 Congenital idiopathic cataract
 Congenital cataract associated with ocular anomalies/systemic disease
 Acquired cataract
The worldwide prevalence of childhood blindness ranges 
from 0.03% in high-income countries to 0.12% in undevel-
oped countries. The causes of severe visual impairment and 
blindness are varied and complex: glaucoma accounts for 
4.2%–5.0% of blindness in the pediatric population.2–4
Genetics and pathogenesis
The genetics of glaucoma is a developing area of research 
with most of the genetic tendency for glaucomas yet to be 
 disclosed. Further, in most populations, the majority of cases 
do not have an identified genetic mutation, and, where the 
mutation is known (GLC3A, GLC3B, and GLC3C loci), the 
genes often account for only a small proportion of cases.5 
However the identification of genes and the spectrum of 
mutations causing childhood glaucoma will have both basic 
and clinical relevance. It may help in early treatment and 
diagnosis, carrier detection and genetic counseling, population 
screening, and prenatal diagnosis, for establishing genotype–
phenotype correlations and prognosis, understanding patho-
genesis, and the development of better treatment strategies.
Several pathogenetic mechanisms are known to contrib-
ute to the development of childhood glaucoma. Regardless 
of the cause, it results in a reduced aqueous outflow at the 
level of the trabecular meshwork (TM). TM formation begins 
around the fourth month of gestation. The mesenchymal 
cells of the TM form a wedge-shaped structure between 
the corneal endothelium and the deeper stroma. Schlemm’s 
canal (SC) forms from a venous plexus anterior to the TM 
which becomes visible in the 16th week of gestation and by 
24 weeks it is present throughout the entire circumference. 
By 36 weeks, SC and the outer collecting channels are clearly 
defined and connected by intercanalicular links. The devel-
opment of this system continues postnatally: an adult-like 
configuration is achieved by 8 years.6–8 In PCG, the develop-
mental arrest of tissues derived from cranial neural crest cells 
can lead to anterior iris insertion, thickened trabecular beams, 
compressed trabecular sheets, iris processes, and insertion 
of the fibers of the ciliary muscle into the TM.
Clinics
The age of onset and the magnitude of the elevated IOP 
largely determine the clinical manifestation and their high 
variability. Very high IOP can present dramatically in a 
newborn as cloudy, enlarged corneas. A slower rise in IOP 
results in a less acute presentation with buphthalmos but no 
corneal clouding or photophobia. The timing of the pressure 
rise influences the clinical features, owing to the limited 
potential of the young eye to deform.
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Glaucoma from any cause in a neonate or infant is asso-
ciated with the classic triad of epiphora (excessive tearing), 
photophobia (hypersensitivity to light), and blepharospasm 
(squeezing of the eyelids). Any combination of these symp-
toms should arouse suspicion of glaucoma in an infant or 
child. These conditions are secondary to the corneal irritation 
that accompanies corneal epithelial edema caused by elevated 
IOP. Beyond the age of 3 years, children are more likely to 
present with progressive myopia or strabismus.
Epiphora may at first be attributed to a non-patent tear 
drainage system, which is a common condition. Photophobia 
commonly occurs and may be of gradual or sudden onset. 
The parents may first notice that their baby keeps the eyes 
closed when exposed to sunlight. Moderate photophobia may 
be noticed indoors as well; the baby will often keep the eyes 
closed even while eating. Severe photophobia will cause the 
baby to keep the eyes closed constantly or to hide the face 
from bright lighting or even from ordinary lighting. The baby 
may also be seen to rub the eyes frequently during the period 
of apparent discomfort.
Enlargement of the eye (buphthalmos) occurs under the 
influence of the elevated IOP. During the first 3 years of life, 
corneal and scleral collagen are still immature and the young 
eye is vulnerable to the effects of increased IOP with the major 
enlargement occurring at the corneoscleral junction. As the 
cornea and limbus enlarge, Descemet’s membrane and the 
corneal endothelium are stretched and this can result in linear 
ruptures (Haab striae). Haab striae are usually concentric to the 
limbus in the periphery and more typically horizontal centrally 
near or across the visual axis, where associated opacification 
and resultant astigmatism can limit the visual potential.
Glaucomatous optic-disk cupping in infants differs from 
that in adults in two ways: it occurs earlier and more rap-
idly, with severe excavation possible at birth and it is often 
reversible if IOP reduction occurs before irreversible nerve 
atrophy. The younger the child is, the greater the potential 
for disk-cupping reversal.9
The history of blepharospasm, photophobia, and tearing 
is very useful in arousing the suspicion of glaucoma and in 
distinguishing it from other conditions. The suspicion of 
glaucoma in a child should always be treated seriously and 
with urgency to minimize visual impairment. This requires 
examination in a clinic or under anesthesia depending on the 
child’s ability to cooperate.
Diagnosis
A complete ocular assessment including slit-lamp examina-
tion, applanation tonometry, and optic-nerve-head evaluation 
can usually be performed in the office in children over the 
age of 5 years and, with some training, in children as young 
as 3 years.
Other historical information of importance is a family 
history of glaucoma, parental consanguinity, associated 
congenital defects, maternal history of infection (rubella) 
during pregnancy, and birth history (forceps use).10 In older 
children, a history of trauma, ocular surgery, or corticosteroid 
use may be relevant.
The aim of the initial assessment is to rule out glaucoma 
or establish that enough evidence for glaucoma exists to 
justify an examination under anesthesia (EUA) for a more 
complete examination and surgery if indicated. All anes-
thetic drugs alter the IOP of patients with PCG, seemingly 
in relation to the level of anesthesia and as a direct function 
of their effect on hemodynamic changes and cardiovascular 
tone. Multiple exposures to general anesthesia in infants 
and young children may adversely affect the developing 
brain and may cause long-term neurocognitive changes. 
However, the possible anesthetic neurotoxicity concerns 
should be considered within the context of the high risk of 
blindness from glaucoma in children not adequately assessed 
or surgically managed.11–14 EUAs performed solely to make 
the diagnosis prior to referral for surgery should be avoided; 
it is best that the ophthalmologist undertaking the initial 
EUA be capable of performing the definitive surgery under 
the same anesthetic, to avoid unnecessary anesthesia and a 
delay in treatment.
The examination of a child suspected to have glaucoma 
should begin by assessing the overall appearance and visual 
behavior of the infant or child, including the signs of nys-
tagmus or strabismus. Ambient illumination can be reduced 
to allow a neonate or infant to open their eyes, permitting 
a more complete examination by penlight or portable slit 
lamp. Through observation alone it may be possible to assess 
the presence of corneal edema, lacrimation, photophobia, 
blepharospasm, and the relative and actual size of both eyes. 
When indicated, it is important to examine the patient’s 
parents, as the presence of subtle signs of anterior-segment 
dysgenesis in the parents may change the genetic advice 
given and alter the management of subsequent siblings.
Measuring the IOP in children can be challenging, as 
it is potentially influenced by many factors such as type of 
tonometer, cooperation, eye movements, anesthesia, and 
corneal conditions like edema or opacities. Therefore, IOP 
is among the least accurate and most variable of all the 
parameters measured when assessing a child for glaucoma. 
The diagnosis of pediatric glaucoma should never be made 
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on the basis of elevated IOP alone but based on the overall 
clinical findings and investigation results.
The gold standard for measuring IOP is Goldmann appla-
nation tonometry using a Perkins handheld tonometer, during 
EUA, with a blue filter after installation of topical anesthesia 
and fluorescein. The “Tono-Pen®” (Reichert Technologies, 
Depew, NY, USA) is an electronic tonometer often used with 
pediatric patients, but it is known to overestimate the IOP 
in children compared with applanation tonometry in both 
normal children and those with glaucoma.15–17 The iCare 
portable rebound tonometer (iCare Finland Oy, Helsinki, 
Finland) can measure IOP without the installation of topical 
anesthetic in both upright and supine positions by rolling the 
baby into a lateral position, and may be better tolerated than 
noncontact methods. It has a similar reliability to a Tono-Pen, 
with a tendency to overestimate IOP in known or suspected 
glaucoma cases compared with applanation tonometry.18–24
Ideally, the eyes should be in the primary position and 
motionless as pressure readings may be altered by eye 
 movements. Avoid measuring the IOP when using a lid specu-
lum or when the baby is crying or squeezing his or her lids, as 
all of these may falsely elevate the IOP. The IOP should be 
measured several times in both eyes and prior to pupil dilation, 
as it can also affect the measurements. It is advisable to use 
the same type of tonometer for serial examinations.
Anterior-segment examination of a neonate or infant 
is a very important part of the examination, not only with 
regard to the diagnosis of glaucoma but also in determining 
the type of glaucoma.
Medications may help clear the cornea and improve 
visualization of anterior-segment structures and angle fea-
tures with gonioscopy. The cornea should be examined for 
the presence of posterior embryotoxon, corneal enlargement 
or edema, and Descemet’s membrane splits (Haab striae). 
Excluding primary corneal disease is important, and a use-
ful distinguishing feature is the absence of corneal or ocular 
enlargement.
Examining the iris and pupil for abnormalities is fun-
damental to determine the type of glaucoma, as they may 
suggest a secondary cause of glaucoma. Iris abnormalities, 
such as peripheral corneal adhesions, may indicate the pres-
ence of Axenfeld–Rieger anomaly, especially in the setting 
of posterior embryotoxon. Diffuse iris atrophy may indicate 
a subtle variant of aniridia, whereas inferior sectoral iris 
atrophy or distortion may indicate a colobomatous process. 
Similarly, determining the coexistent presence of lens opaci-
ties and glaucoma may influence the diagnosis and the choice 
of glaucoma surgery.
The purpose of gonioscopy is to differentiate primary 
from secondary glaucoma.25 In other words, it is crucial in 
making the correct diagnosis, as this determines the most 
appropriate management and prognosis. In the normal new-
born eye, the iris usually inserts posterior to the scleral spur. 
The anterior extension of the ciliary body is seen as a distinct 
band anterior to the iris insertion. The iris insertion into the 
angle is flat, because the angle recess has not yet matured. 
The formation of the angle recess, characteristic of the adult 
angle, in which the iris turns slightly posteriorly before insert-
ing into the ciliary body, develops in the first 6 to 12 months 
of life. The TM has no acquired pigmentation and appears 
thicker and more translucent than that of the adult.26,27
In PCG, the immature angle appearance is thought to 
result from the developmental arrest of tissues derived from 
cranial neural crest cells in the third trimester of gestation. 
The severity of angle abnormality depends on the stage at 
which the angle development has been arrested. The iris 
insertion of eyes with PCG is higher than normal and the 
peripheral iris inserts to the TM and the scleral spur is not 
visualized. The level of insertion may vary in different areas 
of the angle, and, in very immature angles, pale amorphous 
tissue may be present in the angle.
Corneal enlargement usually occurs before 3 years of 
age. Serial corneal diameter measurements are useful in 
establishing the diagnosis and in the monitoring the progres-
sion of glaucoma. The normal horizontal neonatal diameter 
is around 10 mm, increasing by about 1 mm during the first 
year of life. A corneal diameter greater than 11 mm in a 
newborn and 12 mm in an infant less than 1 year old is very 
suggestive of raised IOP and with Haab striae it is diagnostic. 
A measurement of greater than 13 mm in a child of any age 
is abnormal. During EUA, the corneal diameter is measured 
with calipers from limbus to limbus – usually only horizontal 
corneal diameter or both horizontal and vertical. An increas-
ing corneal diameter in a vulnerable eye suggests inadequate 
control of IOP and requires further treatment.
The definitive role for pachymetry in the evaluation of 
childhood glaucoma is currently uncertain. Central corneal 
thickness should not be used to “adjust” an IOP measure-
ment, as in the adult, but rather taken into consideration in 
the overall context of the examination.
In general, thinner corneas tend to cause tonometers to 
underestimate IOP, whereas thicker corneas tend to cause 
overestimation of IOP compared with the “true” value. 
Central corneal thickness can be increased due to stromal 
edema, thickening (congenital or postoperative), or scarring. 
Children with PCG and JOAG have thinner central corneas 
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than normal subjects.28–30 In contrast, corneal thickness is 
known to be increased in patients with congenital aniridia 
and in aphakia following congenital cataract surgery.31–34
Dilated fundoscopy is performed once the IOP has been 
measured and anterior-segment examination has been com-
pleted, as dilation can spuriously elevate the IOP and alter 
the angle appearance. The most important and sensitive 
parameter for both diagnosis and determination of progres-
sion in pediatric glaucoma is the optic-disk appearance, 
because it is not influenced by anesthesia or by the effect 
of growth. Optic-nerve size, the cup–disk ratio, focal areas 
of rim loss, and nerve fiber layer defects following dilation 
should be carefully recorded.35–37 An increase in disk cupping 
is definite evidence of poorly controlled glaucoma and the 
need for further treatment, regardless of IOP measurement 
obtained.
Another evidence of glaucoma is the loss of hypermetro-
pia or the presence of myopia. Progressive myopia may sug-
gest inadequate IOP control, especially if seen in the setting 
of progressive axial length increase.38–43
Classification
Primary congenital glaucoma
“PCG” refers to a specific form of developmental glaucoma 
that has an isolated maldevelopment of the TM (isolated tra-
beculodysgenesis) not associated with other developmental 
ocular anomalies or ocular disease that can raise the IOP 
(Figure 1). PCG is classified, according to age of onset of 
signs, into: neonatal or newborn onset (0–1 month), infantile 
onset (.1–24 months), and late onset or late recognized 
(.2 years).
PCG is the most diffused non-syndromic glaucoma 
in infancy,44,45 but it has a variable reported incidence 
worldwide. A higher prevalence has been observed in those 
cultures and groups with an increased rate of consanguinity, 
especially in those groups in which cousin–cousin marriages 
are common. PCG occurs in 1 per 10,000–20,000 live births 
in Western countries.46,47 The incidence rises in the Middle 
East to 1 per 8,200 live births in Palestinian Arabs and 1 per 
2,500 live births in Saudi Arabians. The highest reported 
incidence is 1 per 1,250 in Slovakian Gypsies.48
It is usually bilateral (70%), with the severity of involve-
ment frequently asymmetrical. There is a slightly higher 
prevalence in males, but familial cases tend to have an 
equal sex distribution.49 Most cases of PCG are sporadic. 
A family history of glaucoma is reported in 10%–40% of 
cases associated with autosomal recessive inheritance and 
variable penetrance ranging from 40% to 100%. The risk 
of PCG in siblings and offspring in patients with no history 
of parental consanguinity is low (,5%), but it is prudent to 
examine the siblings and offspring of patients, especially in 
the first 6 months of life. To date, three PCG loci have been 
identified. GLC3A is the major locus for PCG, accounting 
for 85%–90% of all familial cases.50 It has been mapped 
to the short arm of chromosome 2p21, the GLC3B locus 
to chromosome 1p36, and GLC3C to chromosome 14q24, 
with more loci speculated to exist. Mutations of the GLC3A 
locus affect the gene CYP1B1 which encodes for an enzyme 
cytochrome P4501B1 that has been postulated to participate 
in the development and function of the eye.51,52 CYP1B1 
mutations are more commonly seen among familial rather 
than sporadic cases, and they are associated with a variable 
expressivity and penetrance.
The pathogenesis of PCG remains uncertain. The 
immature angle appearance results from the developmen-
tal arrest of tissues derived from cranial neural crest cells 
in the third trimester of gestation. Obstruction to outflow 
was thought to be due to the presence of an impermeable 
 membrane (Barkan’s membrane) but this has never been 
verif ied  histopathologically. Known histopathological 
changes in PCG include an anterior iris insertion, thickened 
trabecular beams, compressed trabecular sheets with loss of 
intertrabecular spaces, iris processes, and insertion of the 
fibers of the ciliary muscle into the TM.53,54
PCG usually presents in neonates or infants, with the 
majority presenting at less than 6 months of age. Clinically, 
PCG is characterized by elevation of IOP, which causes 
stretching of the tissues of the eye and enlargement of the 
globe (buphthalmos). The enlargement of the globe and 
stretching of the cornea can produce breaks in Descemet’s 
membrane, known as “Haab striae”. The elevated IOP 
also causes corneal edema, which manifests with epiphora 
and photophobia. Blepharospasm is likely a result of the 
 photophobia. Children with PCG usually present for evalu-
ation because their parents notice something unusual about Figure 1 Bilateral buphthalmos in PCG.
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the appearance (corneal opacification or enlargement of the 
eye) of the patient’s eyes or their behavior (photophobia and 
blepharospasm). The severity of the signs and symptoms 
varies depending on the duration and magnitude of the IOP 
elevation. Further, the timing of IOP elevation also affects 
the signs, as a child with late-onset PCG after the age of 
3 years will not present corneal enlargement.
Gonioscopy of the eye with PCG reveals an anterior 
insertion of the iris directly into the TM. The iris insertion is 
typically flat, and it may vary at different areas of the angle, 
with some portions of the iris inserting anterior and other 
areas posterior to the scleral spur. Changes seen due to the 
physical stretching of structures from elevated IOP include 
a thin and hypopigmented iris stroma, a peripheral scallop-
ing of the posterior pigmented iris layer and hyperemic iris 
vessels with circumferential vessels running tortuously in 
the peripheral iris or on the ciliary body.55
Juvenile primary open-angle glaucoma
“JOAG” is a relatively rare form of childhood glaucoma, 
accounting for only 0.2% of childhood glaucoma cases. It 
typically presents after 4 years of age and up to 35 years. It 
is classified as a primary glaucoma of childhood, along with 
PCG. There is often a strong family history of glaucoma, and 
it is often inherited as an autosomal dominant trait. Up to 20% 
of patients have mutations of the MYOC (myocilin)/TIGR 
( trabecular meshwork-inducible glucocorticoid response) 
gene at the GLC1A locus on chromosome 1q23.5. Although 
it is not well understood how mutations in the MYOC gene 
cause glaucoma, they appear to do so by affecting trabecular 
outflow.56
JOAG differs from primary open-angle glaucoma in 
its age of onset and magnitude of IOP elevation. JOAG is 
typically asymptomatic and is discovered incidentally on 
routine eye examination or screening due to a family  history. 
Although JOAG is a bilateral disease, there can often be 
marked asymmetry between the two eyes.
Typically, these patients present optic-disk excavation and 
an extremely high IOP, sometimes greater than 40–50 mmHg, 
with a normal angle appearance and no signs of other ocular 
anomalies or systemic disease. As the disease presents after the 
age of 4 years, there are no signs typically seen in PCG, such 
as corneal edema and enlargement, Haab striae, or any other 
symptoms usually associated with congenital glaucoma.
Secondary childhood glaucoma
Secondary childhood glaucomas occur as the result of condi-
tions of ocular anomalies present at birth, which may or may 
not be associated with systemic signs, or systemic diseases 
present at birth. This category also includes acquired condi-
tions that are not inherited or congenital but which develop 
after birth. Glaucoma that develops after cataract surgery is 
excluded from the acquired-condition category to highlight 
its frequency.
Glaucoma associated with non-acquired  
ocular anomalies
Glaucoma related to congenital ocular anomalies may be 
present at birth or may develop over time, so regular life-
long monitoring is necessary. A variety of congenital ocular 
anomalies are associated with glaucoma and some also have 
associated systemic conditions. These anomalies include the 
following.
“Axenfeld–Rieger anomaly” refers to usually bilateral 
abnormalities of the peripheral cornea, peripheral iris, 
and angle. Clinically, posterior embryotoxon (prominent 
 Schwalbe’s line) with iris attachments is seen. “Axenfeld–
Rieger syndrome” refers to these ocular features in asso-
ciation with systemic anomalies such as hypertelorism, 
periumbilical skin folds, and dental abnormalities.57,58
“Peters anomaly” is a mesenchymal dysgenesis of the 
anterior segment, presenting with a spectrum of ocular 
abnormalities. This condition is characterized by the pres-
ence of a congenital central corneal opacity with defects in 
stroma, Descemet’s membrane, and the endothelium.59 Peters 
anomaly can be associated with systemic abnormalities 
(Peters Plus Syndrome).
“Aniridia” is a bilateral disorder characterized by the 
variable absence of a normal iris, often associated with other 
ocular anomalies (optic-nerve hypoplasia, keratopathy, early 
onset cataract and glaucoma).60
Other conditions that may be associated with glaucoma 
are ectropion uveae, persistent fetal vasculature, microcornea, 
sclerocornea, and those anterior-segment anomalies that do 
not fit into any recognized category.61–64
Glaucoma associated with non-acquired  
systemic disease or syndrome
Systemic disease present at birth may be associated with 
ocular signs that include glaucoma.
“Sturge–Weber syndrome” (SWS), or encephalotrigemi-
nal angiomatosis, is a congenital neurocutaneous vascular 
syndrome, which can potentially involve skin, eye, and brain. 
It is the commonest phacomatosis associated with glaucoma 
that occurs at any time from birth to adulthood and arises 
from elevated episcleral venous pressure.65,66
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“Neurofibromatosis” is another phacomatosis that may 
present with iris abnormalities, like ectropion uveae and 
glaucoma, before the systemic disease is apparent.62,67
“Ectopia lentis”, a displacement of the lens from its 
normal position due to distended or broken zonules, can 
present as an isolated ocular anomaly or be associated 
with other ocular or systemic findings (like Marfan syn-
drome, homocystinuria, and Weill–Marchesani syndrome). 
 Glaucoma is a common and often a serious complication. 
The mechanism can be either angle closure from a displaced 
lens or an open-angle mechanism.68–70
“Congenital rubella syndrome” includes cardiac defects, 
neurologic abnormalities, bone defects, hepatospleno-
megaly, and endocrine abnormalities. Ocular disease affects 
78%–88% of congenital rubella syndrome patients and 
includes keratitis, corneal edema, iris hypoplasia, chronic 
iridocyclitis, cataracts, pigmentary retinopathy, and glaucoma 
that may be secondary to congenital malformation of the 
angle or to chronic iridocyclitis or cataracts.71
Glaucoma associated with acquired conditions
This category includes conditions which are not inherited or 
present at birth but which develop after birth.
Pediatric uveitis may cause glaucoma. The majority 
of cases of pediatric uveitis are idiopathic, while the most 
common identifiable cause of uveitis in children is juvenile 
idiopathic arthritis (41%–67%). Uveitic glaucoma is mul-
tifactorial due to chronic cellular trabecular obstruction, 
trabeculitis, and peripheral anterior synechiae. Children with 
uveitis develop more severe glaucoma than adults and they 
progress rapidly to severe visual loss.72–74
Traumatic glaucoma, acute or chronic in onset, are 
secondary to blunt or penetrating ocular trauma. The patho-
genesis is multifactorial and the mechanisms of raised IOP 
include uveitis, hyphema, angle recession, ghost-cell glau-
coma, and dislocated lens.75
“Corticosteroid-induced glaucoma” is an increase in IOP 
as a result of corticosteroid therapy. Increased IOP is time 
and dose dependent and may occur with various forms of 
corticosteroids (topical, inhaled, oral, etc). The pathogenesis 
is an increased resistance to outflow of aqueous resulting from 
changes in TM microstructure due to an abnormal extracel-
lular protein deposition.76
Glaucoma secondary to intraocular tumors in children is 
a relatively rare event. Patients with acquired glaucoma sec-
ondary to tumors can be symptomatic with acute glaucoma 
due to the fast growth of the tumor, or symptom-free in case 
of a progressive, slow growing tumor. Retinoblastoma and 
intraocular melanoma are the most common malignant 
tumors leading to secondary glaucoma, due to outflow 
obstruction by tumor cells or secondary hemorrhage.77,78
Retinopathy of prematurity (ROP)-induced glaucoma 
occurring in an eye with a history of ROP and anatomic 
changes due to the ROP (retrolental fibroplasia, papillary 
block) or treatment for ROP (choroidal detachment, ante-
rior displacement of the lens–iris diaphragm, hyphema). 
The mechanisms of raised IOP can all result in narrowing 
of the AC angle with the potential for secondary angle 
closure.79,80
Glaucoma following cataract surgery
Glaucoma is one of the most serious complications occurring 
after infantile cataract surgery for congenital idiopathic cata-
ract, cataract associated with ocular or systemic syndromes, 
or acquired cataract. It is usually open angle and can develop 
during the immediate postoperative period or years later. It 
includes both aphakic and pseudophakic eyes. Although 
early cataract surgery has been shown to be associated with 
improved visual outcomes, it is also important to remember 
that the earlier cataract surgery is performed, the higher is 
the risk of secondary glaucoma.
Medical therapy
Medical therapy is generally used as temporizing IOP-
lowering treatment before surgery or as adjuvant treatment 
postoperatively in case of partially successful procedures for 
refractory glaucoma in infants and young children. Corneal 
edema resolution, thanks to aqueous suppression prior to 
surgery, is another important achievable goal.
As a primary approach to childhood glaucoma, medica-
tion alone usually has a provisional efficacy, particularly in 
PCG. However, medical treatment should be considered first-
line for JOAG, uveitis-related glaucoma, and glaucoma after 
cataract removal. Different kinds of childhood glaucoma may 
respond differently to topical hypotensive drugs (Table 2). In 
the case of PCG, universally recognized as a surgical condi-
tion, pharmacologic therapy may help to alleviate pain and 
photophobia and to recover corneal transparency for a better 
view of the AC angle, especially before angle surgery.
If a goniosurgery is planned, miosis induced with 
 pilocarpine can increase angle opening, improving surgical 
accessibility and reducing consecutive anterior synechiae. 
Beta-blockers must be instilled with the lowest dosage and 
frequency, better if in gel formulation, because of cardio-
respiratory side effects in children.81–85 Oral carbonic anhy-
drase inhibitors are not indicated for infants due to possible 
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Table 2 Medication use in childhood glaucoma
Drugs Mechanism Efficacy Side effects
Beta-blockers Aqueous decrease 
• Ciliary epithelial inhibition 
• Anterior ciliary artery vasoconstriction
20%–25% iOP reduction Topical: apnea, asthma, cough, bradycardia
Carbonic anhydrase 
inhibitors
Aqueous decrease 
•  HCO3- and CO2 interconversion  
inhibition
.25% iOP reduction 
(oral . topical)
Oral: lethargy, paresthesia, anorexia, diarrhea, 
metabolic acidosis, urolithiasis, growth  
suppression, enuresis, allergy 
Topical: metabolic acidosis
Adrenergic agonists Aqueous decrease 
• Uveoscleral outflow increase
Short-term iOP reduction Topical: allergy, mydriasis, tachyarrhythmia 
Brimonidine: CNS toxicity (lethargy, apnea)
Prostaglandin analogues  
or prostamides
Uveoscleral outflow increase 25%–35% iOP reduction Topical: eyelash growth, hyperemia, iris 
pigmentation change, uveitis
Miotics TM outflow increase 
• Ciliary muscle stimulation
Miosis for angle surgery Topical: miosis, myopic shift, brow ache
Abbreviations: CNS, central nervous system; iOP, intraocular pressure; TM, trabecular meshwork.
Table 3 Side effects in the mother and baby attributed to anti-
glaucomatous drugs
Drugs Side effects
Beta-blockers Bradycardia and cardiac arrhythmia in fetus 
or breastfed child 
Timolol is approved by the American 
Academy of Pediatrics during lactation with 
punctal occlusion
Alpha agonists Central nervous system depression, apnea, 
and hypotension in the neonate/infant
Carbonic anhydrase  
inhibitors
Possible teratogenic, metabolic acidosis in 
the breastfed child 
it is not known if they are excreted in the milk 
Dorzolamide is approved by the American 
Academy of Pediatrics during lactation with 
punctal occlusion
Prostaglandin analogues Uterine contractions and premature labor
Parasympathomimetics Cholinergic effects in the newborn
metabolic acidosis, urolithiasis, lethargy, paresthesia, and 
anorexia; topical formulations are less efficient but safer, 
especially brinzolamide.86–90 Brimonidine, an adrenergic ago-
nist, must be avoided in neonates, infants, and young  children, 
in consideration of central nervous system  toxicity.91–94 In 
PCG, prostaglandin analogus and prostamides are mainly 
used as adjunctive medication.95–98
JOAG is more responsive to topical anti-glaucoma 
therapies, with prostaglandin analogs or beta-blockers usually 
prescribed as first drugs.
The different systemic pharmacokinetics in children, 
due to high ocular/plasmatic volume ratio and metabolic 
immaturity, could result in atypical or unpredictable effects 
with topically applied glaucoma medications. Therefore, it is 
important to advise parents or caregivers to perform punctal 
occlusion to reduce systemic absorption, and to pay special 
attention to adverse symptoms because of children’s inability 
to verbalize them.99–101
Limitations in performing visual-field and morphofunc-
tional testing of the optic-nerve head in children make follow-
up more complicated. Thus, it is necessary to consider all 
available data to choose or reassess the target IOP.
Considering the lack of safety and effectiveness evaluations 
in pediatric patients, implementation of legislation in the USA 
and the European Union has encouraged pediatric-specific 
product development and testing in the last few years.102
In pregnant/lactating glaucoma patients, an appropriate 
balance of the risk to the fetus during therapy against risks 
to the mother in case of treatment reduction or suspension 
is mandatory. In the first trimester, all medications should 
be avoided (especially prostaglandin analogues, due to 
an increased risk of miscarriage), whereas in the second 
and third trimesters beta-blockers, alpha agonists, topical 
carbonic anhydrase inhibitors, and parasympathomimetics 
(miotics) could be used. During lactation, the instillation 
of alpha agonists and oral carbonic anhydrase inhibitors is 
contraindicated103–106 (Table 3).
Finally, a surgical approach must be considered whenever 
medical therapies are revealed to be unsatisfactory in less-
ening the progression of optic-nerve damage. Nevertheless, 
if a risk of severe postoperative complications in end-stage 
glaucomas exists, it is more advisable to be content with 
partial IOP control.
Surgical therapy
Surgery is the nodal point of the management of refractory 
childhood glaucoma, so it is crucial to opt for a forward-
looking strategy, considering the long life expectancy of the 
child. In effect, the first surgery is often the child’s best chance 
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of long-term success, so it is important to choose the most 
appropriate procedure, and it is better if this is performed by 
an experienced surgeon under safe general anesthesia.107–109
Childhood glaucoma surgery has a higher complication 
and failure rate than in adult patients because of ocular 
enlargement and an intense inflammatory and healing 
response. In particular, thin and elastic sclera predisposes to 
peritubular leakage and impedes the ability to fashion a sclera 
flap and facilitates AC collapse; thick Tenon capsule prevents 
good filtration; stretched zonules in enlarged eyes can cause 
lens subluxation; and limited orbital space makes access to 
the eye difficult. In addition, compliance and cooperation 
issues can negatively influence the quality of postoperative 
monitoring and follow-up.
Angle surgery (goniotomy, trabeculotomy) is usu-
ally the first-line procedure with the best success rates for 
PCG, whereas it is impractical in glaucoma associated with 
Axenfeld–Rieger anomaly because of iris attachments to 
Schwalbe’s line as well as in uveitic glaucoma because of 
peripheral anterior synechiae. Pilocarpine preoperatively or 
acetylcholine chloride intraoperatively is advisable to achieve 
adequate miosis and protect the lens against trauma by the 
iris. “Goniotomy” is an ab interno angle incision under direct 
gonioscopy, but it is unfeasible with hazy corneas because 
the angle structures are not clearly visible, often even after 
epithelial debridement. Stromal haze and Haab striae may still 
obscure the view. Goniotomy has a low complication rate and 
is a very effective operation with a success  usually ranging 
from 70% to 93% in large series after multiple  surgeries.110–112 
“Trabeculotomy” is the ab externo rupture of the TM obtained 
by dissecting a superficial scleral flap and then identifying and 
entering SC with a metal trabeculotome probe. Complications 
are related to the positioning and manipulation of the probe: 
stripping of Descemet’s membrane, iris prolapse, iridodialysis, 
cyclodialysis, hyphema, bleb formation and hypotony, lens 
subluxation, and cataract.113
As the extent of angle incised is important in some cases, 
circumferential suture trabeculotomy with an illuminated 
microcatheter has been recently introduced to treat the entire 
angle in one session. This surgical technique has a reported 
overall success rate of 80%–90% after 1–4 years.114,115
Combined trabeculotomy-trabeculectomy is sustained to 
be more successful than either procedure performed alone 
and that is the primary procedure of choice.116–118
Trabeculectomy can be performed as a primary surgical 
procedure with satisfactory success rates in cases of repeated 
failed angle surgery and in most secondary glaucomas. 
The application of mitomycin C (MMC) in refractory 
glaucomas can counteract the vigorous wound healing 
response in children, but the complications, especially those 
related to hypotony (shallow or flat AC, hypotony maculopa-
thy, choroidal effusion, suprachoroidal hemorrhage) and to 
bleb formation (blebitis, endophthalmitis, chronic bleb leak) 
often appear to increase.119–123
Aqueous shunt devices (Molteno, Ahmed, and Baerveldt 
implants) offer the most effective long-term IOP management 
in glaucomas that are refractory to other surgical solutions. 
In this procedure, a tube is connected to a reservoir (plate) 
that shunts aqueous from the AC to the equator. Even if avail-
able in smaller pediatric versions, the adult-size implant is 
recommended if obtainable to utilize a larger surface area. In 
eyes with heavily scarred conjunctiva, aqueous shunt surgery 
appears more appropriate. There is no prospective evidence 
that MMC influences shunt surgery outcomes. Despite the 
effectiveness, these devices have a severe complication profile 
related to hypotony (shallow or flat AC, hypotony macul-
opathy, choroidal effusion, suprachoroidal hemorrhage and 
phthisis) or to the tube (tube erosion, occlusion, migration, 
corneal touch, iris touch, and lens touch). Several studies have 
reported success rates around 80% with a mean follow-up 
of 2 years. Even with long-term well-controlled IOP, relapse 
can occur at any stage.124–131
Cyclophotocoagulation with a transscleral diode laser 
(810 nm) has a limited success rate in the long term and retreat-
ment is often required, which disallows the discontinuation of 
medications. Cyclodestruction is usually indicated for chal-
lenging, refractory glaucomas with poor surgical prognoses. 
Complications associated with cyclodiode therapy include: 
hypotony, phthisis, conjunctival burns, uveitis, scleromalacia, 
cataract, retinal detachment, and loss of vision.132–134
Other glaucoma procedures (deep sclerectomy, visco-
canalostomy, canaloplasty, ab interno trabeculotomy with 
Trabectome® [NeoMedix Corporation, Tustin, CA, USA], 
suprachoroidal shunts, TM bypass shunts, and transs-
cleral shunts) promoted in children have not been widely 
embraced because of either the technical complexity in 
buphthalmic eyes or not yet proven efficacy and safety in 
children.135–137
Combining glaucoma surgery with other ocular surgeries 
may potentially increase the risk of complications, prolong 
duration of anesthesia, and render less certain the outcomes. 
However, when more than one procedure is required, consecu-
tive rather than simultaneous surgeries are preferable.
The variations in presentation will dictate when or if 
lens extraction and/or glaucoma surgery is/are necessary, 
generally favoring isolated glaucoma surgery, rather than 
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combined procedures, to minimize risks. In all cases of 
planned corneal surgery, the IOP must be preemptively 
reduced.138 Following successful IOP control with surgery, 
ametropia correction and amblyopia therapy, if indicated, 
are essential to maximize visual potential. Regardless, it is 
important to prepare the patient and parents or caregivers for 
lifelong follow-up and possible future surgeries.
Surgical interventions at the eye Clinic  
of verona, italy
During the period 2000–2013, we evaluated 123 children 
under general anesthesia at the Eye Clinic of Verona in Italy, 
73 males (59%) and 50 females (41%), with an age at onset 
(mean ± standard deviation) of 25±17 months. In 12% of 
cases, the first diagnosis of primary (54%) or secondary 
(46%) glaucoma was made within the first month of life 
(Table 4). Considering 18 patients dropped out, the mean 
follow-up was 4.8±3.7 years (range: 3–13 years), with a 
mean of 102±15 EUAs per year.
The first surgical approach utilized was goniotomy in 
31% of cases, trabeculotomy alone in 36% of cases, and 
combined trabeculotomy-trabeculectomy with or without 
MMC in 33% of cases. As further intervention, when needed, 
trabeculotomy, combined trabeculotomy-trabeculectomy, 
bleb needling, cyclodiode treatment (especially at the begin-
ning of the study period), and Baerveldt device implantation 
were mainly performed.
In the case of primary glaucoma, a mean of 1.5 operations 
was executed, with a mean IOP of 16.1±4.2 mmHg at last 
follow-up (27.8±7.3 mmHg at baseline); in case of secondary 
glaucoma, a mean of 3.2 operations was needed, with a mean 
IOP of 22.8±5.1 mmHg at the last visit (26.6±8.1 mmHg 
preoperatively) (Table 5).
Conclusion
Childhood glaucoma is a challenging disease that needs 
an appropriate approach in dedicated centers with specific 
experienced surgeons. A good prognosis is a function of early 
diagnosis, proper surgical indication, and correct technical 
execution.
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